Category: News

For researchers, Life Science companies and healthcare innovators, single-cell sequencing represents a new frontier of untapped potential. It’s not just about exploring the cellular landscape, cell by cell, it’s about harnessing these insights to develop new treatments and redefine the future of healthcare. Embracing this technology could be the key to staying at the forefront of a rapidly evolving industry.

The partnership between the Institut du Cancer Montpellier (ICM) and Acobiom is to confirm the predictive value of two patented RNA signatures

Innate immunity’s role in pancreatic cancer is complex. It impacts inflammation, immune surveillance, and the tumor microenvironment, influencing disease progression and potential treatments.

Innovation in pancreatic cancer: Acobiom develops the 1st blood-based diagnostic to identify the patients most likely to benefit from FOLFIRINOX as 1st-line treatment.

Pancreatic ductal adenocarcinoma (PDAC, representing more than 90% of pancreatic cancer cases is a highly lethal cancer, and chemotherapy is a key treatment for advanced PDAC. Gemcitabine chemotherapy is still an important component of treatment. Although, according to several clinical trials (Conroy, T. et al. N Engl J Med. 2011; Von Hoff, D. et al.…
Read more

• CE marked test for patients with pancreatic ductal adenocarcinoma
• Prediction of response to first-line gemcitabine-based chemotherapy
• Developed and validated with real world data and samples

Pancreatic cancer is a highly lethal cancer. For several years, gemcitabine has been one of the main chemotherapies used to treat this cancer. But there is no routine biomarker to predict its efficacy.
Dr. Noelle LoConte presented the results of using GemciTest® in a confirmatory study, which shows the predictive performance of this in-vitro diagnostic based on PCR technology and a blood RNA signature.

The French Association of Competitiveness Poles (FACP) awards ACOBIOM the hi-France label, the label of innovative companies to invest in.

Based on Real-World Data and Real-World Evidence, ACOBIOM contributes to better therapeutic decisions and thus allows to give the right treatment to the right patient.

Based on its proprietary database of gene expression profiles and its scientific expertise, ACOBIOM selected a panel of genes to measure inflammation in organs and blood. This Digital or Real-Time PCR assay allows the company to extend its range of services.